FIGURE 2.

Summary of evidence of germline pathogenic variants in 27 cancer‐predisposing genes in the National Comprehensive Cancer Network guidelines in May 2023. The evidence of germline pathogenic variants in 27 cancer‐predisposing genes has been extracted from the National Comprehensive Cancer Network (NCCN) guidelines. ²³ , ²⁴ , ²⁵ The evidence level in the NCCN guidelines is as follows: very strong: prospective cohort studies in a population‐based setting have demonstrated risk; strong: traditional case–control studies or more than three case–control studies including those with cases ascertained by commercial laboratories or those without controls from the same population (traditional case–control study: a retrospective study that compressed patients with a disease or specific outcome with patients without the disease or outcome). ²³ , ²⁴ , ²⁵